Table 2 Human studies on selenoprotein molecular biomarkers
From: Relevance of selenoprotein transcripts for selenium status in humans
Study | Baseline daily Se intake (μg) Mean ± SD | Baseline plasma Se level (ng/ml) Mean ± SD | Selenoprotein gene expression in WBC |
|---|---|---|---|
UK, SELGEN study, n = 39, both sexes, 6 week. Se intervention (Pagmantidis et al. 2008) | Not presented | 93.9 ± 1.7 | Lymphocyte Up-regulation: SPS1—1.15 (1.06–1.23) SelK—1.11 (1.04–1.19) Sep15—1.11 (1.02–1.20) |
Denmark, n = 20, 18–40 years. old men, 1 week Se intervention (Ravn-Haren et al. 2008a) | 49.8 ± 13.6 | 113.2 ± 12.2 | Leukocyte No effect: GPx1, TrxR1 SePP1 |
Denmark, PRECISE pilot study, n = 105, both sexes, up to 5 years. Se intervention (Ravn-Haren et al. 2008b) | 49.8 ± 13.6 | 93 ± 11.2 | Leukocyte No effect: GPx1 |
UK, n = 39, both sexes, 28 week. Se intervention (Sunde et al. 2008) | 48 ± 14 | 89.2 ± 12.5 | Whole blood No effect and no association between Se status and GPx1, GPx3, GPx4, SePP1, SepW, SepH |
Poland, n = 47 healthy men (Reszka et al. 2009) | 24.2 ± 17.4 (unpublished data) | 54.3 ± 14.6 | Leukocyte No association between Se status and GPx1, GPx3, SePP1, Sep15 |